One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Pha...( New Findings Also Demonstrate Treatme...)

New Findings Also Demonstrate Treatment Results in Improvements in Physical

Function and Health-Related Quality of Life

SAN FRANCISCO, Oct. 27 /PRNewswire/ -- More than half of patients receiving every four week subcutaneous injections of golimumab (CNTO 148) 50 mg and 100 mg, an investigational therapy, experienced sustained improvements in the joint and skin symptoms of active psoriatic arthritis through six months with results sustained through one year. Golimumab-treated patients also experienced improvements in health-related quality of life (HRQOL) in the placebo-controlled portion of the study (through week 24) along with the substantial improvements in physical function and arthritis and psoriasis components of the disease. These findings were presented at the American College of Rheumatology (ACR) annual meeting.

"These results demonstrate long-term efficacy of every four week dosing with golimumab in improving physical symptoms and functional ability as well as improving quality of life," said Arthur Kavanaugh, M.D., Professor of Medicine, University of California, San Diego, School of Medicine, and lead study investigator. "The sustained effects of golimumab as demonstrated in these study findings are encouraging for both the physicians treating this condition and for the many patients living with this potentially debilitating disease."

In the study, Golimumab - A Randomized Evaluation of Safety and Efficacy in Subjects with Psoriatic Arthritis Using a Human Anti-TNF Monoclonal Antibody (GO-REVEAL), 52 percent and 61 percent of patients receiving golimumab 50 mg and 100 mg, respectively, achieved at least 20 percent improvement in arthritis signs and symptoms as measured by American College of Rheumatology (ACR 20) response compared with 12 percent of patients receiving placebo (P < 0.001) at week 24. Through one year, 78 percent of patients continuing in the golimumab 50 mg group and 74 percent of patients contin
'/>"/>